David Feinstein, MD
Endocrinology · Dallas, TXNPI 1609888965
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 43.3% of the total. Reporting peaked in 2020 at $5,005 and has fallen 90.2% since, to $490 in 2025.
Across 304 payments — averaging $33.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$4K
- AbbVie$888
- Mannkind Corporation$747
- Merz North America, Inc.$674
- Novo Nordisk$627
- Insulet Corporation$490
- plus $2K from 34 others
What the payments were for
- Speaking & faculty fees$4,40043%
- Food & beverage$5,66755%
- Education$1171%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 19 | $4,435 |
| AbbVie(2 entities) | 50 | $888 |
| Mannkind Corporation | 34 | $747 |
| Merz North America, Inc. | 3 | $674 |
| Novo Nordisk | 25 | $627 |
| Insulet Corporation | 33 | $490 |
| Sanofi-aventis U.S. LLC | 14 | $397 |
| AstraZeneca | 16 | $259 |
| Amgen(2 entities) | 13 | $212 |
| Abbott | 9 | $166 |
| Boehringer Ingelheim | 8 | $130 |
| Dexcom, Inc. | 6 | $117 |
| Valeritas, Inc. | 8 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $107 |
| Merck | 7 | $104 |
| Lilly USA, LLC | 6 | $84 |
| Regeneron Healthcare Solutions, Inc. | 5 | $67 |
| IBSA Pharma Inc. | 4 | $54 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| Sequel Med Tech, LLC | 3 | $51 |
| Johnson & Johnson | 3 | $47 |
| Galderma Laboratories, L.p. | 3 | $43 |
| Zealand Pharma US, Inc. | 2 | $33 |
| Medtronic(2 entities) | 2 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $27 |
| Companion Medical, Inc. | 4 | $27 |
| Ascensia Diabetes Care US Inc. | 2 | $26 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Bigfoot Biomedical Inc | 1 | $22 |
| Gilead | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $20 |
| Corcept Therapeutics | 1 | $20 |
| Intuity Medical Inc | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Novartis | 1 | $15 |
| Tolmar, Inc. | 1 | $15 |
| Optos, Inc. | 1 | $14 |
| Halozyme Inc | 1 | $13 |
| Avion Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$4,400
- TZIELD$136
- Ozempic$119
- Saxenda$116
- AFREZZA$115
How this compares
Too few endocrinology providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $264,690 |
| MounjaroTirzepatide | 126 | $164,419 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 80 | $95,634 |
| FarxigaDapagliflozin Propanediol | 74 | $87,040 |
| JardianceEmpagliflozin | 52 | $75,780 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $70,519 |
| FiaspInsulin Aspart (Niacinamide) | 30 | $33,257 |
| TrulicityDulaglutide | 23 | $31,232 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $26,393 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $25,059 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $24,056 |
| InvokanaCanagliflozin | 15 | $23,959 |
| JanuviaSitagliptin Phosphate | 19 | $21,738 |
| NovologInsulin Aspart | 52 | $20,005 |
| HumalogInsulin Lispro | 52 | $17,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $627 | $317,951237 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $84 | $214,381213 claims |
| AstraZenecaFarxiga | $259 | $87,04074 claims |
| Boehringer IngelheimJardiance | $130 | $75,78052 claims |
| Johnson & JohnsonInvokana | $47 | $23,95915 claims |
| MerckJanuvia | $104 | $21,73819 claims |
| AbbVieSynthroid | $888 | $12,086107 claims |
| Sanofi-aventis U.S. LLCLantus | $397 | $2,41115 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $2,371215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Texason file to place this against a meaningful peer group, so we don't.
Other endocrinology in Dallas
- Uma GunasekaranDallas$0
- Ananya JhaveriDallas$0
- Leili RahimiDallas$0
- Gabrielle PriceDallas$0
- Israel HartmanArlington$520K
- Donald GardnerHouston$13K
- Jaime CastroFort Worth$8K
- Basma AtaallahHouston$950
- Eric DealHouston$0
- Anwar MoryanDenton$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.